سعر اي في-جلوبيولين 50 مجم / مل 0.5 جم فيال 2022

I.v-globulin 50 mg/ml (5%) 0.5g vial: human normal immunoglobulin for intravenous administration, listed in Egypt under Korea Green Cross (EIMC as local agent) in the immunoglobulin category.

• Most common in the US ALYGLO trial (>=5%): headache, nausea/vomiting, fatigue, nasal/sinus congestion, rash, arthralgia, diarrhea, myalgia, infusion-site pain/swelling, abdominal pain, cough and dizziness.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• History of anaphylactic or severe systemic reaction to human immune globulin; IgA-deficient patients with antibodies to IgA and a history of hypersensitivity.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Boxed warning (IGIV class): thrombosis may occur; risk factors include advanced age, immobilization, hypercoagulable states, prior thrombosis, estrogens, central catheters, hyperviscosity and cardiovascular risk factors.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Boxed warning (IGIV class): renal dysfunction, acute renal failure, osmotic nephrosis and death may occur; ensure patients are not volume-depleted and monitor renal function and urine output.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Severe hypersensitivity reactions may occur; stop the infusion and treat (have epinephrine available).General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Other IGIV risks: hyperproteinemia/increased viscosity/hyponatremia, aseptic meningitis syndrome, hemolysis, transfusion-related acute lung injury, and possible transmission of infectious agents (plasma-derived).General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Other drugs / IV solutionsAdminister separately; do not mix with other products. Passively transferred antibodies may cause misleading positive serological test results.DailyMed (U.S. National Library of Medicine)

• No human data on drug-associated risk; immune globulins cross the placenta increasingly after 30 weeks of gestation.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• No human data during lactation; weigh breastfeeding benefits against maternal need.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Assess renal function (BUN, serum creatinine) before the first infusion and periodically; consider baseline blood viscosity in patients at risk of hyperviscosity.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

English text not available for this section.